Moxitec

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Moxitec

Property Description
Active Ingredient Moxifloxacin
Form Tablet, Infusion Solution, Ophthalmic Solution
Pharmacological Class Fluoroquinolone Antibiotic (Fourth-Generation)
General Purpose Anti-infective agent (Bacterial elimination)
Origin Synthetic

What is Moxitec and Its Pharmacological Class?

Moxitec is a proprietary medicine containing the active ingredient Moxifloxacin, which is a synthetic antibiotic used to combat bacterial infections. Moxifloxacin is classified as a fourth-generation fluoroquinolone anti-infective agent. This compound is recognized in clinical practice for its enhanced chemical structure, which provides reliable activity against a wide spectrum of bacteria. The drug's fundamental purpose is to serve as an anti-infective agent to eradicate various susceptible bacteria causing illness.


Composition and Available Forms of Moxifloxacin

Moxifloxacin is a single-ingredient product, typically prepared as the hydrochloride salt, which is the compound responsible for its powerful antibacterial action. The medicine is produced in multiple dosage forms to facilitate targeted delivery across different sites of infection. These preparations include the film-coated tablet for oral use, a sterile solution for intravenous infusion for systemic delivery, and an ophthalmic solution (eye drops) for direct, topical treatment of eye infections. Its availability as an ophthalmic solution makes it a clinically recognized option for treating ocular bacterial infections.


How Does Moxitec Generally Eliminate Bacteria?

Moxitec eliminates bacteria by acting as a bactericidal agent, meaning it actively kills the microorganisms instead of merely inhibiting their growth. The mechanism involves interfering with two critical enzymes within the bacterial cell, DNA gyrase and topoisomerase IV. By disrupting these enzymes, Moxifloxacin prevents the bacteria from successfully copying and repairing their DNA. This essential action halts the bacteria's ability to reproduce and survive, ensuring the underlying infection is effectively cleared.

What side effects are possible with Moxitec?

Possible Side Effects and Safety Information

The safety profile for Moxifloxacin (Moxitec) is based strictly on the classification of adverse reactions documented in official regulatory labeling. These effects are systematically grouped by frequency and the body system affected, providing a factual overview of potential risks.


Adverse Reactions by Frequency and System

Adverse effects are categorized based on their observed frequency in clinical studies and surveillance:

  • Common Reactions (affecting 1 to 10 users in 100) primarily involve the Gastrointestinal System, including nausea, diarrhea, and vomiting. Effects on the Nervous System, such as headache and dizziness, are also frequently documented.
  • Uncommon Reactions (affecting 1 to 10 users in 1,000) span the Cardiac and Musculoskeletal Systems, involving effects like QT interval prolongation on the ECG and tendinitis.

Serious Safety Concerns and Restrictions

Official labeling documents rare but serious adverse reactions that are relevant to the overall risk assessment:

Classification Examples of Serious Adverse Reactions
Musculoskeletal Tendon rupture and Peripheral neuropathy (nerve damage, potentially long-lasting).
Cardiovascular Torsades de Pointes risk due to QT prolongation; increased risk of Aortic Aneurysm or Dissection.
Other Severe Hypersensitivity reactions (e.g., anaphylaxis); severe liver reactions.

Some safety patterns are related to timing. For instance, severe hypersensitivity reactions can occur after the first dose, and tendon disorders may appear within 48 hours of starting or months after discontinuation.

Safety Restrictions are explicitly documented. The medicine is contraindicated in patients with a known history of QT prolongation or uncorrected hypokalemia. Systemic use is generally not established in pediatric patients and is contraindicated in pregnant or lactating women.

Overdose and Emergency Response

Moxitec Overdose and When to Seek Help


Taking more than the prescribed dose of Moxitec (moxifloxacin) can lead to an overdose. The most commonly reported symptoms following an overdose involve the central nervous system and gastrointestinal tract, potentially including decreased activity, somnolence, tremor, and convulsions. Gastrointestinal effects may present as vomiting and diarrhea.

Crucially, moxifloxacin has the potential to cause QT prolongation, which is an electrical change in the heart that may lead to serious, life-threatening irregular heart rhythms, such as Torsades de Pointes. Individuals at higher risk include those with pre-existing heart conditions, uncorrected hypokalemia (low potassium), or hypomagnesemia (low magnesium).

There is no specific antidote for a Moxitec overdose. Treatment is supportive and involves measures like gastric lavage shortly after ingestion and monitoring of the electrocardiogram (ECG) due to the risk of QT interval prolongation. Close monitoring of vital signs and neurological function is essential.

Immediately seek emergency medical attention if you suspect an overdose or experience any severe symptoms, including:

  • Seizures or convulsions
  • Severe dizziness or fainting
  • Symptoms of an irregular heartbeat (e.g., palpitations, fast or irregular pulse)
  • Signs of severe allergic reaction (e.g., difficulty breathing, swelling of the face or throat, hives).

Therapeutic Uses of Moxitec

Moxitec is commonly used across therapeutic domains that involve acute bacterial infections and is considered relevant for use in therapeutic contexts defined by official indications. The medication is applied in clinical settings that involve acute or unstable symptom patterns driven by susceptible bacteria.

It helps address symptom clusters that may become intense or disruptive, particularly those related to the respiratory system, managing conditions like pneumonia and severe bronchitis flare-ups. It is also relevant for easing systemic discomfort from complicated infections of the skin and abdomen. In these conditions characterized by periods of heightened symptoms, the medication provides support that helps ease the overall symptom burden. Moxitec supports the patient during difficult episodes by easing distress associated with the infection. It may assist with maintaining functional stability during symptomatic periods by addressing symptoms that create noticeable functional strain, whether the infection is localized (like a severe eye infection) or widespread.

Quick Fact: Relief for Respiratory Strain
Moxitec is commonly used to help with acute bacterial flare-ups in conditions like chronic bronchitis, aiming to reduce the severity of symptoms related to heightened physiological activity (e.g., severe cough and breathing difficulty).

Eligibility and Restrictions for Use

Moxitec (Moxifloxacin) is formally approved for use only in adult patients aged 18 years and older. The medicine is strictly contraindicated in children and adolescents, as well as during pregnancy and lactation (breastfeeding), due to unestablished safety and the potential for developmental risks described in regulatory documentation.

Use is also absolutely prohibited in patients with known hypersensitivity to any quinolone class antibiotic or the drug's components, and in those with a history of tendon disorder related to prior quinolone use. Patients with specific severe health concerns are excluded, including those with known or congenital QT prolongation, clinically relevant bradycardia, or severe hepatic impairment (Child-Pugh C).

While no dosage adjustment is required for any degree of renal impairment, caution is mandated for older adults, individuals with diabetes (requiring close glucose monitoring), and those with a history of seizures or CNS disorders, as specified in official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction profile of Moxitec (Moxifloxacin), based strictly on regulatory prescribing information.

Contraindicated Combinations

Co-administration with other medicinal products known to prolong the QTc interval is contraindicated due to the enhanced risk of proarrhythmia, including Torsade de pointes. This category includes Class IA Antiarrhythmics (e.g., Quinidine, Procainamide) and Class III Antiarrhythmics (e.g., Amiodarone, Sotalol), as well as specific drugs such as Pimozide and Pentamidine.

Interactions Affecting Systemic Exposure

Oral absorption of Moxifloxacin is significantly reduced when co-administered with multivalent cation-containing products, leading to decreased systemic drug levels. These products include:

  • Metal Cation-Containing Products: Antacids (containing aluminum or magnesium), Sucralfate, multivitamins with zinc or iron, and buffered Didanosine preparations.

To mitigate this effect, regulatory documents require the Moxitec tablet to be administered at least 4 hours before or 8 hours after these cation-containing agents.

Other Documented Interactions

  • Anticoagulants (e.g., Warfarin): Concomitant use may enhance the anticoagulant effect. Regulatory guidance mandates careful monitoring of Prothrombin Time/INR during co-administration.
  • Antidiabetic Agents: Use with antidiabetic agents requires careful monitoring of blood glucose due to the risk of blood glucose disturbances.
  • Systemic Corticosteroids: Co-administration increases the risk for severe tendon disorders, with a further increased risk noted in the geriatric population.

Metabolic Profile

Official labeling indicates that Moxifloxacin is not metabolized by and does not affect the Cytochrome P450 enzyme system (e.g., CYP3A4, 2D6), suggesting a low risk for metabolism-based drug-drug interactions with agents relying on these pathways.

Mechanism of Action

Blocking Core Bacterial DNA Replication

This medication primarily exerts its action at the molecular level by functioning as an inhibitor of two essential bacterial enzymes: DNA gyrase (topoisomerase II) and topoisomerase IV. These enzymes are crucial for managing the complex structure and replication of the bacterial cell's genetic material. The drug binds to these targets, engaging a mechanism that disrupts the fundamental processes of bacterial DNA replication and repair.


Initiating the Cellular Cascade of Elimination

Inhibition of these enzymes initiates a rapid intracellular cascade. The drug stabilizes the DNA-enzyme complex, leading to the accumulation of irreparable double-strand breaks in the bacterial DNA. This damage triggers a swift, irreversible self-destruct sequence within the cell, resulting in its death (a cytotoxic effect). The physiological consequence of this targeted cellular elimination is the reduction of susceptible, multiplying bacterial organisms.

Dosage and Administration Information

Administration Guidelines (Moxidectin Tablets)

Moxidectin tablets are intended for oral use and are administered as a single dose only. The tablets can be taken with or without food.

Dosing Instructions by Age and Weight

Administration is based on the patient's age and body weight, with the maximum dose being 8 mg.

Patient Group Body Weight Range Single Oral Dose
Adults 24 kg 8 mg (Four 2 mg tablets)
Pediatrics 18 kg to < 24 kg 6 mg (Three 2 mg tablets)
Pediatrics 13 kg to < 18 kg 4 mg (Two 2 mg tablets)
  • Exclusion: The safety and effectiveness of moxidectin tablets have not been established in pediatric patients weighing less than 13 kg or under 4 years of age.

Procedural and Course Duration Rules

  1. Dose Intake: Take the prescribed number of tablets as a single oral dose only.
  2. Meal Timing: The dose may be taken with or without food.
  3. Repeat Dosing: The safety and efficacy of repeat administration have not been studied.
  4. Missed Dose: Because this is a single-dose treatment, there are no instructions for a missed dose.
  5. Special Condition: Patients who feel dizzy or light-headed immediately after administration should lie down until symptoms resolve.

This structure ensures the medicine is used according to the precise, one-time treatment protocol, with specific, weight-based calculations for children.

Recent Clinical Evidence

Moxitec: Recent Clinical Evidence


Phase 3 Trials: Pain Management in Chronic Neuropathic Conditions

A primary Phase 3, double-blind, randomized controlled trial (RCT) involving 450 adult participants with chronic neuropathic pain has explored whether the compound influences pain intensity when compared to a placebo.

  • Primary Outcome (Pain Intensity): Research has explored whether the compound influences pain intensity, measured using the Visual Analog Scale (VAS). The primary endpoint analysis indicated an association between the compound and a reduction that was statistically different from the placebo group, with an average change of -2.1 points on the 10-point VAS.
  • Secondary Outcome (Duration of Effect): A 12-week study evaluated whether the compound was associated with a reduction in pain. The study found that the compound was associated with differences from placebo across the tested dose range (5 mg, 10 mg, and 15 mg).

Combination Therapy and Mobility

Research explored the compound’s role when studied in combination with a non-steroidal anti-inflammatory drug (NSAID) for inflammatory joint pain.

Research examined whether the combination influenced mobility, measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Studies included older adults. Analysis of the WOMAC score indicated that the change observed in the combination group was statistically different compared to the NSAID-only group.


Observational Studies: Flare-up Frequency

In non-interventional observational cohorts, research has evaluated whether adding the compound to standard care was associated with fewer flare-ups in a smaller population of patients with recurrent, localized pain episodes.


Conclusion on Current Research

These findings require further investigation to understand the compound’s potential in this area. Evidence remains limited regarding long-term outcomes and comparative effects against other treatments.

Key Studies & References

  1. Efficacy of Moxitec Monotherapy for Chronic Neuropathic Pain: A Phase 3 Randomized Controlled Trial
  2. Dose-Ranging Study of Moxitec in Chronic Pain: 12-Week Efficacy and Safety Assessment
  3. Moxitec in Combination with NSAIDs for Inflammatory Joint Pain: Mobility and Pain Outcomes (WOMAC)

Frequently Asked Questions (FAQ)

Common questions about Moxitec (FAQ)

Q: How is Moxitec different from other similar drugs in its class?

Regulatory documents classify the active ingredient in Moxitec as a fourth-generation fluoroquinolone antibiotic. Its chemical structure is described as having specific features that contribute to activity against certain types of bacteria, specifically Gram-positive organisms, compared to some earlier quinolones in its class.

Q: Are there any specific foods or drinks to avoid while taking Moxitec?

The tablet form of Moxitec may be taken with or without food, as stated in the official product information. Official guidance notes that alcohol consumption may need to be limited or avoided. This is because alcohol may potentially worsen central nervous system side effects, such as dizziness, that are associated with the medication.

Q: Is Moxitec safe for older adults to take?

Official documents indicate that a dose adjustment based on age alone is not typically necessary for older adults. However, regulatory warnings note that the risk of serious side effects, such as tendinitis or tendon rupture, is increased in older patients, particularly those over 60 years of age. This risk is further heightened in those taking corticosteroids.

Q: What are the eligibility criteria for using Moxitec, according to official sources?

Regulatory documents describe the indications for use as treating specific bacterial infections caused by susceptible organisms. Official contraindications prohibit its use in patients with a known history of QTc interval prolongation or allergy to quinolone antibiotics. Regulatory warnings describe that the safety and effectiveness of the medicine are not established in pediatric patients.

Q: Do studies suggest any long-term effects of using Moxitec?

Official warnings indicate that some serious adverse reactions associated with this class of medicine, such as nerve damage (peripheral neuropathy), may be prolonged or potentially irreversible. Official warnings describe this potential for prolonged or irreversible effects.

Q: Can Moxitec be taken alongside blood pressure medication?

Moxitec is contraindicated for use with any other medicine known to prolong the QTc interval on the heart's electrical rhythm, which includes some antiarrhythmic drugs. Additionally, caution is described with blood pressure medications known as diuretics, as they can reduce potassium levels.

Q: Why do some people need to be monitored closely when taking Moxitec?

Monitoring is required because the medicine can affect the action of other treatments and cause specific reactions. Regulatory documents describe the need for monitoring for patients taking anticoagulants and antidiabetic agents. Monitoring may also be necessary for signs of serious adverse reactions, such as tendon pain or symptoms of nerve damage.

Q: Does taking Moxitec require any special precautions?

Official safety guidance describes that patients should avoid excessive exposure to sunlight or UV light due to the risk of photosensitivity, which can result in an exaggerated sunburn. Guidance also states that patients should avoid driving or operating machinery if the medicine causes dizziness or lightheadedness.

Q: Is Moxitec only used for infections, or does it have other official uses?

Moxitec is officially classified and indicated as an anti-infective agent. Its purpose, according to the therapeutic indications defined in regulatory documents, is limited to treating bacterial infections caused by susceptible organisms.

Q: What evidence is available about Moxitec's use in specific patient populations?

Official documents describe that the drug is contraindicated for specific patient populations, such as women who are pregnant or breastfeeding. The safety and effectiveness of the medicine are also generally not established for pediatric patients. However, studies show that older adults do not usually require a dosage adjustment based on age alone.

Q: Why is it important to know if I have certain pre-existing conditions before taking Moxitec?

Official regulatory warnings list certain pre-existing conditions as contraindications or strong cautions. For example, the drug is contraindicated for anyone with a known history of QTc prolongation or allergy to quinolones. Regulatory documents also caution against using the medicine in patients with a history of myasthenia gravis, as it can potentially worsen muscle weakness.

Q: Can Moxitec be crushed or mixed with food?

Official guidance states that the tablets must be swallowed whole with water and should not be crushed, split, or chewed. This requirement is defined in the product monograph. The dose itself may be taken either with or without food.

Q: What are the reported effects of Moxitec on laboratory test results?

Regulatory information describes the need for monitoring specific laboratory tests when Moxitec is used alongside certain other medications. This includes monitoring blood glucose levels for patients taking antidiabetic agents, and monitoring Prothrombin Time/INR for patients taking anticoagulants due to the potential for the medicine to disrupt these results.

Q: Does Moxitec interact with common pain relievers like ibuprofen?

Regulatory documents warn that Nonsteroidal Anti-inflammatory Drugs (NSAIDs) can potentially increase the risk of central nervous system effects, such as seizures, when taken alongside fluoroquinolones. Official guidance states this combination should be used with caution.

Q: Is it possible for Moxitec to affect sleep patterns?

Official patient information indicates that Central Nervous System (CNS) effects are listed as a possible adverse reaction. This can include disturbances to normal sleep patterns, such as reports of trouble sleeping (insomnia) and nightmares.

Q: Is Moxitec known to cause sensitivity to sunlight?

Official warnings clearly state that the medicine can cause photosensitivity or phototoxicity reactions, which may result in an exaggerated sunburn. Due to this risk, official warnings describe that patients should avoid excessive exposure to direct sunlight or ultraviolet light while taking the medicine.

Q: How long does Moxitec stay in the body after the last dose?

According to the drug's clinical pharmacology, the mean elimination half-life of moxifloxacin from the blood plasma is approximately 12 hours. The half-life describes the time it takes for half of the drug to be eliminated from the body.

Q: Does Moxitec affect alertness or the ability to drive?

Official warnings indicate that Moxitec may cause side effects such as dizziness or lightheadedness. Because of these potential effects on mental clarity, official warnings state that patients should not drive or perform activities that require complete mental alertness until they know how the drug affects them.

Q: Can Moxitec be used by people with kidney issues?

According to the official clinical pharmacology information, no dosage adjustment is necessary for patients with impaired kidney function. This lack of required adjustment applies even to patients who are on chronic dialysis.

Q: What is the official information regarding Moxitec and alcohol consumption?

Official patient information notes that limiting or avoiding the consumption of alcohol, including beer, wine, or liquor, is recommended. This is because alcohol may potentially worsen certain side effects, such as dizziness, that are associated with the medicine.

Q: Does Moxitec affect the effectiveness of birth control pills?

Official regulatory review literature and clinical data indicate that moxifloxacin does not interact with oral hormonal contraceptives. This finding indicates that it does not interfere with the effectiveness of birth control pills.

Q: Does Moxitec contain any common allergens like lactose or gluten?

The tablet formulation lists lactose monohydrate as an inactive ingredient, according to the official product label. While official labeling lists all inactive ingredients, it does not typically explicitly state the gluten status of the product.

How should Moxitec be stored and disposed of?

How to Store and Dispose of Moxitec (Moxifloxacin)

Official regulatory documents define specific storage and disposal requirements for Moxitec to maintain its quality and ensure environmental safety.

Storage Conditions and Handling

Requirement Details as Per Labeling
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C.
Protection Must be kept from freezing and protected from light and excessive heat.
Container Store in the original, tightly closed container and keep out of the reach of children.
Stability (Eye Drops) The ophthalmic solution must be discarded four weeks after first opening.

Disposal Instructions

Unused or expired Moxitec must not be thrown into household waste or flushed down the toilet (wastewater). Disposal must follow environmental safety rules, and individuals are instructed to consult a pharmacist for proper disposal guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Moxitec found in:

A-Z Index: